Physician Scientist, Cancer Biology – Providence, RI
Physician Scientist in Cancer Biology – Applicants with outstanding research accomplishments in basic cancer research and/or translational oncology.
Related Articles
CDC confirms first known severe case of H5N1 bird flu in the U.S.
The U.S. has confirmed its first known severe human infection of H5N1 bird flu, in a person in Louisiana.
Assessing alternative strategies for measuring metabolic risk
npj Digital Medicine – Qiao et al. recently investigated the ability of dual-energy X-ray absorptiometry (DXA) scans and a smartphone app to provide detailed body…
FDA approves ensartinib for ALK-positive locally advanced or metastati
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced…
Circumventing Cancer Resistance
Traditional and new cancer therapies often become stymied due to tumor resistance, but why resistance arises and how to avoid it remain important questions in…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Isshiki et al. demonstrate that EZH2 inhibitors re-activate immune synapse functions between B cell lymphomas and T cells, sensitizing lymphomas to T cell immunotherapies. EZH2 inhibition enhances killing…
Prioritizing caregiver mental health to promote child health
Pediatric Research – Prioritizing caregiver mental health to promote child health
NOT-OD-25-047: 2024 NIH Public Access Policy
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: 2024 NIH Public Access Policy NOT-OD-25-047. OD
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Patients with follicular lymphoma (FL) who progress within 24 months of front-line therapy (POD24) have poor outcomes, but clinical factors predicting earl